WASHINGTON (AP) – Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira.
However, U.S. sales of the company’s recently approved hepatitis C pill came in below expectations, underscoring concerns that the company is too reliant on Humira.
Sales of Humira, which is the world’s top-selling prescription drug, increased 18 percent to $3.1 billlion. Humira is approved to treat more than a dozen conditions including rheumatoid arthritis, psoriasis and Crohn’s Disease. But it will start losing patent protection next year and could eventually face competition from Amgen Inc., which is developing a biosimilar version of the drug.
That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. Company executives have predicted Viekira could reach annual sales of $3 billion by the end of 2015 with further growth in 2016 as the drug expands into new countries.
But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to a survey compiled by analyst Robyn Karnauskas of Deutsche Bank.
